Dermatology

>

Latest News

Upadacitinib achieves 50% reduction in Total Vitiligo Area Scoring Index at 48 weeks | Image Credit: © Liga Cerina - © Liga Cerina - stock.adobe.com.
Upadacitinib achieves 50% reduction in Total Vitiligo Area Scoring Index at 48 weeks

October 29th 2025

A pair of phase 3 trials showed that AbbVie's daily upadacitinib 15 mg led to a 50% reduction in T-VASI 50 and a 75% reduction in F-VASI 75 at 48 weeks among adolescents 12 years and older.

Baricitinib demonstrates sustained hair regrowth in adolescents with alopecia areata | Image Credit: © Alex Papp - © Alex Papp - stock.adobe.com.
Baricitinib demonstrates sustained hair regrowth in adolescents with alopecia areata

October 24th 2025

Fall Clinical: Lebrikizumab-lbkz shows sustained skin clearance with one dose every 8 weeks | Image Credit: © arhat - © arhat - stock.adobe.com.
Fall Clinical: Lebrikizumab-lbkz shows sustained skin clearance with one dose every 8 weeks

October 24th 2025

Fall Clinical: Roflumilast creams 0.15%, 0.05% reduce sleep disruptions in AD patients 2 years, older | Image Credit: © Gorodenkoff  - © Gorodenkoff - stock.adobe.com.
Fall Clinical: Roflumilast creams 0.15%, 0.05% reduce sleep disruptions in AD patients 2 years, older

October 24th 2025

FDA expands adalimumab-aaty's pediatric indications to include hidradenitis suppurativa, uveitis | Image credit: Contemporary Pediatrics
FDA expands adalimumab-aaty's pediatric indications to include hidradenitis suppurativa, uveitis

October 17th 2025

Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.